NR1H4 and metabolic dysfunction-associated steatohepatitis: In MASH (55) and liver fibrosis (56), obecholic acid (OCA) can activate FXR and then inhibit CYP7A1, reduce BAs synthesis, reduce the toxicity of bile acid accumulation in hepatocytes, down-regulate pro-inflammatory factors, such as alleviating liver inflammation.